Hematologic Malignancies Program

Ask the Expert

Get answers to your Myelodysplastic Syndromes questions.

Note: This is for informational purposes only. Doctors cannot provide a diagnosis or individual treatment advice via e-mail. Please consult your physician about your specific health care concerns.

Please install flash player to see this video.

Cancer Center Virtual Tour

Related Content

The Program for Hematologic Malignancies is built on a long-standing tradition of excellence. From its inception as an extramural program of the National Cancer Institute, the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) has been at the forefront of developing and testing new therapies for hematologic malignancies.

As one of the largest experimental therapeutics programs on the East Coast, we offer experimental therapies for all stages of leukemia, lymphoma, Hodgkin's disease and multiple myeloma. Our center is a member of the Myeloproliferative Disorders Research Consortium, an NIH-funded international clinical trials group focusing on myeloproliferative disorders.

Our team of experts includes internationally and nationally recognized leaders in this field, and we continue to set the standard for treating patients with:

Acute and chronic leukemia
Lymphomas, including Hodgkin's disease
Multiple myeloma and other similar disease disorders
AIDS-related lymphomas

Working with referring physicians to provide patients with the best possible care, we treat all types of hematologic malignancies. Our experts work together throughout the treatment process to ensure that patients receive the highly individualized program of care they need while undergoing complex, aggressive therapies.

Dr. Maria Baer is co-grantee on two new research awards studying blood cancers:
V Foundation grant, with Feyruz Rassool, Ph.D. and Alan Tomkinson, Ph.D. for "Targeting Abnormal DNA Repair Pathways in Leukemia" and NIH Competitive Grant with Amy Davidoff, Ph.D. and Sheila Weiss Smith, Ph.D. for "Erythropoietic Stimulating Agents in Treatment of MDS" to study the costs, risks, and benefits of treatments for MDS that affect more than 10,000 elderly patients each year.
Study Shows Promising Results for Novel Combination Treatment for Relapsed Multiple Myeloma Patients
Welcome: Dr. Amy S. Kimball
UMGCC Becomes Member of Myeloproliferative Disorders Research Consortium
Read a Q&A with Maria Baer, M.D., head of Hematologic Malignancies at UMGCC
UMGCC Named a Center of Excellence by the Myelodysplastic Syndromes Foundation

This page was last updated on: November 19, 2009.